Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos Inc (NASDAQ: AIMD) delivers innovative healthcare solutions through its pioneering work in low-dose interferon therapeutics and AI-powered diagnostics. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, strategic partnerships, and technological breakthroughs.
Access timely reports on VELDONA clinical trial progress, AI Nose platform deployments, and regulatory milestones. Our curated collection features earnings announcements, research collaborations, and product innovation updates directly from corporate sources. All content undergoes strict verification to ensure accuracy and compliance with financial disclosure standards.
Key focus areas include autoimmune disease research advancements, veterinary medicine applications, and cross-industry implementations of olfactory sensing technology. Regular updates provide insights into how Ainos integrates biologics with artificial intelligence to address critical healthcare challenges.
Bookmark this page for verified updates on Ainos' progress in redefining patient care through science-driven solutions. Visit regularly to stay informed about emerging opportunities in biotech innovation and AI-driven healthcare.
Ainos announces significant progress in the clinical trials of its AI Nose-powered Ainos Flora device, designed for rapid, non-invasive detection of bacterial, fungal, and common sexually transmitted infections in women. The trials, conducted at four major medical centers in Taiwan, successfully tested 75 cases, validating the AI algorithm's accuracy through real-world data incorporation and comprehensive data standardization.
Building on current trial success, Ainos aims to develop a next-gen Ainos Flora with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trials. The new device will feature improvements for at-home testing, addressing growing demand for decentralized healthcare solutions. The STI testing market is projected to reach $256 billion by 2028, with POCT accounting for 31%.
Ainos' ongoing innovation in AI and medical technology is supported by over 50 patents. The Ainos Flora device won the 2021 iF's Medicine/Health Design Award, highlighting its effectiveness and user-friendly design for home healthcare.
Ainos announced a clinical study for a new VELDONA-based drug aimed at treating feline chronic gingivostomatitis (FCGS). The study will evaluate the efficacy of low-dose oral interferons and is expected to run from May 24, 2024, to March 31, 2025. This initiative follows a Memorandum of Understanding with SIDSCO Biomedical and aims to expand Ainos' presence in the pet care market. VELDONA, initially approved in 1985 for feline leukemia and canine parvovirus, has shown systemic effects in various species, making it a promising candidate for FCGS treatment. The trial will include 30 cats and assess health improvements and potential steroid dosage reductions.
Ainos, a diversified healthcare company, released its Q1 2024 financial results. The company reported a strategic shift from COVID-19 rapid test kits, affecting near-term revenues, with Q1 revenue dropping to $20,729 from $49,164 in Q1 2023. Cost of revenues also decreased to $26,754 from $100,848. Despite this, gross profit improved, narrowing the loss to $6,025 from a $51,684 loss a year ago. Total operating expenses rose to $3.11M, attributed to higher clinical trial fees and research costs. Net loss widened to $3.31M from $2.52M. Recent financing efforts secured $9M in growth capital and an additional $1.75M in January 2024, bolstering Ainos' position for continued growth. CEO Chun-Hsien Tsai emphasized the focus on AI Nose and VELDONA technologies, exploring new markets, and advancing clinical studies.
Ainos, Inc. raises $9 million in growth capital through a convertible note with an existing shareholder. The capital will be used to scale up the company's VELDONA and AI Nose growth initiatives. Ainos aims to advance its AI Nose platform and VELDONA investigational new drugs, propelling the company forward in advancing clinical studies and pursuing out-licensing opportunities.
FAQ
What is the current stock price of Ainos (AIMD)?
What is the market cap of Ainos (AIMD)?
